Morgan Stanley
CTKB icon

Morgan Stanley’s Cytek Biosciences CTKB Stock Holding History

Morgan Stanley’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Sell
701,792
-1,017,083
-59% -$4.34M ﹤0.01% 4567
2026
Q1 		$7.51M Buy
1,718,875
+17,890
+1% +$84.5K ﹤0.01% 3811
2025
Q4 		$8.59M Buy
1,700,985
+237,844
+16% +$1.1M ﹤0.01% 3734
2025
Q3 		$5.08M Buy
1,463,141
+313,020
+27% +$1.18M ﹤0.01% 4133
2025
Q2 		$3.91M Buy
1,150,121
+404,644
+54% +$1.35M ﹤0.01% 4256
2025
Q1 		$2.99M Sell
745,477
-343,984
-32% -$1.78M ﹤0.01% 4324
2024
Q4 		$7.07M Buy
1,089,461
+22,403
+2% +$133K ﹤0.01% 3689
2024
Q3 		$5.91M Buy
1,067,058
+172,694
+19% +$979K ﹤0.01% 3842
2024
Q2 		$4.99M Buy
894,364
+50,843
+6% +$305K ﹤0.01% 3876
2024
Q1 		$5.66M Buy
843,521
+7,365
+0.9% +$58.3K ﹤0.01% 3821
2023
Q4 		$7.63M Buy
836,156
+221,863
+36% +$1.4M ﹤0.01% 3582
2023
Q3 		$3.39M Buy
614,293
+43,997
+8% +$353K ﹤0.01% 4014
2023
Q2 		$4.87M Buy
570,296
+53,332
+10% +$478K ﹤0.01% 3793
2023
Q1 		$4.75M Buy
516,964
+327,379
+173% +$3.52M ﹤0.01% 3828
2022
Q4 		$1.94M Sell
189,585
-25,457
-12% -$342K ﹤0.01% 4492
2022
Q3 		$3.17M Buy
215,042
+18,399
+9% +$239K ﹤0.01% 4062
2022
Q2 		$2.11M Buy
196,643
+78,756
+67% +$784K ﹤0.01% 4495
2022
Q1 		$1.27M Buy
117,887
+112,808
+2,221% +$1.52M ﹤0.01% 4831
2021
Q4 		$82K Sell
5,079
-35,836
-88% -$750K ﹤0.01% 6551
2021
Q3 		$875K Buy
+40,915
New +$962K ﹤0.01% 5134

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley's CTKB Position: Q2 2026 in Review

Morgan Stanley reduced its Cytek Biosciences (CTKB) stake by 59% in Q2 2026, selling an estimated $4.34M and leaving 701,792 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #4567.

Morgan Stanley first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $8.59M in Q4 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Morgan Stanley held 701,792 shares of Cytek Biosciences worth $3.11M as of Q2 2026.
  • Morgan Stanley sold 1,017,083 Cytek Biosciences shares in Q2 2026, an estimated $4.34M.
  • Cytek Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4567 holding.
  • Morgan Stanley first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Cytek Biosciences position peaked at $8.59M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.